179 related articles for article (PubMed ID: 37686699)
1. A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis.
Lee SK; Kwon JH; Lee SW; Lee HL; Kim HY; Kim CW; Song DS; Chang UI; Yang JM; Nam SW; Kim SH; Song MJ; Kim JH; Lee A; Yang H; Bae SH; Han JW; Nam H; Sung PS; Jang JW; Choi JY; Yoon SK; Shim DJ; Kim D; Kim M
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686699
[TBL] [Abstract][Full Text] [Related]
2. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.
Cao F; Shi C; Zhang G; Luo J; Zheng J; Hao W
BMC Cancer; 2023 Sep; 23(1):873. PubMed ID: 37718456
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
4. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis.
Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Alrashidi I
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365655
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
6. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study.
Zhao C; Xiang Z; Li M; Wang H; Liu H; Yan H; Huang M
J Hepatocell Carcinoma; 2023; 10():1195-1206. PubMed ID: 37521029
[TBL] [Abstract][Full Text] [Related]
8. Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study.
Tan Z; Lu J; Zhu G; Chen L; Wang Y; Zhang Q; Pan T; Wang J; Guo J; Teng G
Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1414-1422. PubMed ID: 34131776
[TBL] [Abstract][Full Text] [Related]
9. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Zheng Y; Xiang Y; Shi H; Lin Z; Cheng S; Zhu J
J Hepatocell Carcinoma; 2024; 11():1079-1093. PubMed ID: 38882440
[TBL] [Abstract][Full Text] [Related]
11. Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study.
Li X; Guo W; Guo L; Lau WY; Ge N; Wang K; Cheng S
Oncotarget; 2018 May; 9(36):24537-24547. PubMed ID: 29849959
[TBL] [Abstract][Full Text] [Related]
12. Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching.
Tang C; He Q; Feng J; Liao Z; Peng Y; Gao J
Front Immunol; 2023; 14():1254158. PubMed ID: 37928530
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Xia WL; Zhao XH; Guo Y; Hu HT; Cao GS; Li Z; Fan WJ; Xu SJ; Li HL
Clin Transl Gastroenterol; 2023 May; 14(5):e00581. PubMed ID: 36920551
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis.
Li XL; Guo WX; Hong XD; Yang L; Wang K; Shi J; Li N; Wu MC; Cheng SQ
Hepatol Res; 2016 Oct; 46(11):1088-1098. PubMed ID: 26783741
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.
Guo L; Wei X; Feng S; Zhai J; Guo W; Shi J; Lau WY; Meng Y; Cheng S
Hepatol Int; 2022 Dec; 16(6):1368-1378. PubMed ID: 36271176
[TBL] [Abstract][Full Text] [Related]
17. Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma.
Xie Q; Yang Y; Hao W; Luo C
Clin Transl Oncol; 2024 May; ():. PubMed ID: 38801510
[TBL] [Abstract][Full Text] [Related]
18. Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year.
Kim Y; Kim JS; Kang B; Kim I; Kim H; Lee WS; Sang YB; Jung S; An C; Kim C; Chon HJ
Cancer Res Treat; 2024 May; ():. PubMed ID: 38810969
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
20. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation.
Zhou Q; An Y; Liu T; Liu Z; Li R; Wang C; Zhou F; Liu C; Zhu K
Int J Hyperthermia; 2022; 39(1):97-107. PubMed ID: 34979845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
